Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00255
|
|||||
Drug Name |
L-carnitine
|
|||||
Synonyms |
(-)-(R)-3-Hydroxy-4-(trimethylammonio)butyrate; (-)-Carnitine; (-)-L-Carnitin; (-)-L-Carnitine; (3-Carboxy-2-hydroxypropyl)trimethyl-ammonium hydroxide, inner salt; (3R)-3-hydroxy-4-(trimethylammonio)butanoate; (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate; (L-3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt; (R)-(3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide; (R)-(3-Carboxy-2-hydroxypropyl)trimethylammonium hydroxide, inner salt; (R)-3-Hydroxy-4-(trimethylammonio)butyrate; (R)-3-Hydroxy-4-trimethylammoniobutyrate; (R)-Carnitine; 1-CARNITINE; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt; 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, inner salt, (2R)-(9CI); 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt; 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, innersalt; 3-carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium; Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, L-(8CI); Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide,inner salt; Bicarnesine; C-1985; Carnicor; Carniking; Carniking 50; Carnilean; Carnitene; Carnitine; Carnitine (L-form); Carnitolo; Carnitor; Carnitor (TN); Carnovis; Carrier; DRG-0211; Gamma-Trimethyl-ammonium-beta-hydroxybutirate; Gamma-Trimethyl-beta-hydroxybutyrobetaine; Karnitin; L-(-)-Carnitine; L-Carnitine inner salt; L-carnitine Base; L-gamma-trimethyl-beta-hydroxybutyrobetaine; Lefcar; Levocarnitina; Levocarnitina [Spanish]; Levocarnitine; Levocarnitine (JAN/USP/INN); Levocarnitine [USAN:INN]; Levocarnitinum; Levocarnitinum [Latin]; Metina; R-(-)-3-hydroxy-4-trimethylaminobutyrate; ST 198; Vitamin B T; Vitamin BT
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Nutritional deficiency [ICD11: 5B7Z] | Approved | [1] | |||
Therapeutic Class |
Vitamins
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C7H15NO3
|
|||||
Canonical SMILES |
C[N+](C)(C)CC(CC(=O)[O-])O
|
|||||
InChI |
InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/t6-/m1/s1
|
|||||
InChIKey |
PHIQHXFUZVPYII-ZCFIWIBFSA-N
|
|||||
CAS Number |
CAS 541-15-1
|
|||||
Pharmaceutical Properties | Molecular Weight | 161.2 | Topological Polar Surface Area | 60.4 | ||
Heavy Atom Count | 11 | Rotatable Bond Count | 3 | |||
Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 3 | |||
XLogP |
-0.2
|
|||||
PubChem CID | ||||||
PubChem SID |
103332887
, 103944816
, 104324626
, 115354359
, 118307976
, 12125266
, 124360711
, 124757780
, 124811873
, 125164584
, 126603600
, 126608844
, 131318133
, 131549872
, 134224069
, 134338232
, 134975930
, 135692459
, 136903840
, 137003561
, 141954380
, 143433319
, 143857297
, 15120307
, 15171033
, 2207
, 24892238
, 29279278
, 3612
, 46475651
, 46505864
, 48416167
, 49747058
, 49833446
, 49867038
, 53788226
, 56312758
, 56320717
, 56320718
, 57326565
, 77300350
, 7849237
, 8145671
, 8157930
, 841764
, 85165027
, 87565251
, 91146345
, 92308023
, 93166761
|
|||||
ChEBI ID |
ChEBI:16347
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | ASCT2 | Transporter Info | Alanine/serine/cysteine/threonine transporter 2 | Substrate | [2] | |
CACT | Transporter Info | Carnitine/acylcarnitine translocase | Substrate | [3] | ||
FLIPT2 | Transporter Info | Fly-like putative transporter 2 | Substrate | [4] | ||
MCT9 | Transporter Info | Monocarboxylate transporter 9 | Substrate | [5] | ||
OCTN1 | Transporter Info | Organic cation/carnitine transporter 1 | Substrate | [6] | ||
OCTN2 | Transporter Info | Organic cation/carnitine transporter 2 | Substrate | [7] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | FLIPT2 | Transporter Info | Km = 20 microM | Oocytes-FLIPT2 | [8] | |
OCTN2 | Transporter Info | Km = 3.5 microM | Human cervical cancer cell line (Hela)-OCTN2 | [9] | ||
OCTN2 | Transporter Info | Km = 2.66 microM | Human embryonic kidney cells (HEK293)-OCTN2 | [10] | ||
OCTN2 | Transporter Info | Km = 4.3 microM | Human embryonic kidney cells (HEK293)-OCTN2 | [11] | ||
OCTN2 | Transporter Info | Km = 10.9 microM | Human embryonic kidney cells (HEK293)-OCTN2 | [11] | ||
OCTN2 | Transporter Info | Km = 14.07 microM | Human enterocyte-like 2 cells (Caco-2)-OCTN2 | [12] | ||
OCTN2 | Transporter Info | Km = 4.8 microM | Oocytes-OCTN2 | [13] | ||
OCTN2 | Transporter Info | Km = 54 microM | Rat brain endothelial cells-OCTN2 | [14] | ||
References | ||||||
1 | L-carnitine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | A polarized localization of amino acid/carnitine transporter B(0,+) (ATB(0,+)) in the blood-brain barrier. Biochem Biophys Res Commun. 2008 Nov 14;376(2):267-70. | |||||
3 | Molecular and functional analysis of SLC25A20 mutations causing carnitine-acylcarnitine translocase deficiency. Hum Mutat. 2004 Oct;24(4):312-20. | |||||
4 | The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J Biol Chem. 2010 Feb 26;285(9):6275-84. | |||||
5 | Histological characterization of orphan transporter MCT14 (SLC16A14) shows abundant expression in mouse CNS and kidney. BMC Neurosci. 2016 Jul 1;17(1):43. | |||||
6 | Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(-/-)) mice. Mol Genet Metab. 2007 Dec;92(4):315-24. | |||||
7 | Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5). Drug Metab Dispos. 2017 Dec;45(12):1240-1244. | |||||
8 | Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. J Biol Chem. 2002 Sep 27;277(39):36262-71. | |||||
9 | beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21;275(3):1699-707. | |||||
10 | Na(+)-coupled transport of L-carnitine via high-affinity carnitine transporter OCTN2 and its subcellular localization in kidney. Biochim Biophys Acta. 2001 Jun 6;1512(2):273-84. | |||||
11 | Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. | |||||
12 | Expression and localization of organic cation/carnitine transporter OCTN2 in Caco-2 cells. Am J Physiol Gastrointest Liver Physiol. 2003 May;284(5):G863-71. | |||||
13 | Functional and pharmacological characterization of human Na(+)-carnitine cotransporter hOCTN2. Am J Physiol Renal Physiol. 2000 Sep;279(3):F584-91. | |||||
14 | Molecular cloning and functional characterization of the OCTN2 transporter at the RBE4 cells, an in vitro model of the blood-brain barrier. Brain Res. 2003 Apr 4;968(1):69-79. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.